Skip to main content
. 2021 Jul 20;8(4):370–379. doi: 10.1016/j.ijnss.2021.07.002

Table 2.

Baseline demographics.

Characteristic Full sample (n = 61) Intervention group (n = 31) Control group (n = 30) χ2/Z/t P
Age 36.18 ± 8.51 (22–62) 36.94 ± 8.45 (22–62) 35.40 ± 8.64 (23–54) 0.120 0.702a
Gender 1.000b
 Male 60 (98.4) 30 (96.8) 30 (100.0)
 Female 1 (1.6) 1 (3.2) 0 (0.0)
Ethnic groups 0.492b
 Han 59 (96.7) 29 (93.5) 30 (100.0)
 Minority 2 (3.3) 2 (6.5) 0 (0.0)
Educational attainment 5.003 0.025c
 College or less 25 (41.0) 17 (54.8) 8 (26.7)
 University or above 36 (59.0) 14 (45.2) 22 (73.3)
Religion 0.604 0.570c
 No 44 (72.1) 21 (67.7) 23 (76.7)
 Yes 17 (27.9) 10 (32.3) 7 (23.3)
Employment status 1.000b
 Employed 54 (88.5) 27 (87.1) 27 (90.0)
 Unemployed 2 (3.3) 1 (3.2) 1 (3.3)
 Sick leave at home 2 (3.3) 1 (3.2) 1 (3.3)
 Retired 3 (4.9) 2 (6.5) 1 (3.3)
Household registry 0.011 1.000c
 Shanghai 37 (60.7) 19 (61.3) 18 (60.0)
 Non-shanghai 24 (39.3) 12 (38.7) 12 (40.0)
Marital status 0.266b
 Single 50 (82) 24 (77.4) 26 (86.7)
 Unmarried with a stable partner 5 (8.2) 2 (6.5) 3 (10.0)
 Widowed 6 (9.8) 5 (16.1) 1 (3.3)
Monthly income (CNY) −1.500 0.134d
 Less than 5,000 12 (19.7) 9 (29.0) 3 (10.0)
 5,000–10,000 26 (42.6) 12 (38.7) 14 (46.7)
 More than 10,000 23 (37.7) 10 (32.3) 13 (43.3)
 Months of HIV diagnosis 25.00 (48.00) 24.00 (56.00) 28.50 (39.25) −0.570 0.569d
 Months of taking ART 21.00 (33.50) 16.00 (41.00) 21.00 (27.75) −0.368 0.713d
Latest CD4+ T-cell count (/μl) −0.168 0.866d
 Less than 300 19 (31.1) 9 (29.0) 10 (33.3)
 300–500 22 (36.1) 13 (41.9) 9 (30.0)
 More than 500 20 (32.8) 9 (29.0) 11 (36.7)
Latest viral load 0.137 0.772c
 Undetectable 46 (75.4) 24 (77.4) 22 (73.3)
 Detectable 15 (24.6) 7 (22.6) 8 (26.7)
ART prescription 0.195b
 Free ART 56 (91.8) 30 (96.8) 26 (86.7)
 TDF+3 TC + EFV 33 (54.1) 19 (61.3) 14 (46.7)
 AZT+3 TC + EFV 7 (11.5) 3 (9.7) 4 (13.3)
 ABC+3 TC + EFV 5 (8.2) 3 (9.7) 2 (6.7)
 TDF+3 TC + LPV/r 3 (4.9) 1 (3.2) 2 (6.7)
 AZT+3 TC + LPV/r 4 (6.6) 2 (6.5) 2 (6.7)
 ABC+3 TC + LPV/r 2 (3.3) 1 (3.2) 1 (3.3)
 AZT+3 TC + NVP 1 (1.6) 1 (3.2) 0 (0)
 ABC+3 TC + NVP 1 (1.6) 0 (0) 1 (3.3)
Self-paying ART 5 (8.2) 1 (3.2) 4 (13.3)
 TDF+3 TC + DTG 2 (3.3) 0 (0) 2 (6.7)
 TDF+3 TC + RAL 1 (1.6) 0 (0) 1 (3.3)
 ABC+3 TC + DTG 1 (1.6) 0 (0) 1 (3.3)
 FTC/TDF + DTG 1 (1.6) 1 (3.2) 0 (0)

Note: Data are n (%), Median (IQR), or Mean ± SD (range). a independent sample t-test; b Fisher’s exact test; c chi-square test; d Wilcoxon rank-sum test. Free ART in China: TDF, 3TC, EFV, AZT, ABC, LPV/r,NVP. Self-paying ART in China: DTG, RAL, FTC/TDF. ART = antiretroviral therapy. TDF = Tenofovir disoproxil. 3TC = Lamivudine. EFV = Efavurebz. AZT = Zidovudine. ABC = Abacavir. LPV/r = Lopinavir/ritonavir. NVP = Nevirapine. DTG = Dolutegravir. RAL = Raltegravir. FTC/TDF = Emtricitabine/Tenofovir disoproxil.